An Open-label, Nonrandomized, Phase 1 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics of Belinostat in Combination with Atazanavir in Patients with Advanced Relapsed/Refractory Solid Tumors or Hematological Malignancies

This is an open-label, nonrandomized, Phase 1 drug-drug interaction (DDI) study to characterize the pharmacokinetics (PK) of belinostat in combination with the strong UGT1A1 inhibitor, atazanavir, in patients with advanced relapsed/refractory solid tumors or hematological malignancies.